# Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

> **NCT06430905** · PHASE1 · TERMINATED · sponsor: **Hookipa Biotech GmbH** · enrollment: 30 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV) Infection

## Interventions

- **BIOLOGICAL:** HB-502 and HB-501 alternating 2-vector therapy Dose Level 1
- **BIOLOGICAL:** HB-502 and HB-501 alternating 2-vector therapy Dose Level 2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06430905
- **Lead sponsor:** Hookipa Biotech GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-07-01
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-07-18
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** business decision
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06430905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06430905, "Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06430905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*